
BioNTech SE
BNTXHealthcare|Biotechnology|DE
$87.51
+1.65 (+1.92%)
DCF Value
$46.34
Tangible Book / Share
$64.71
Cash / Share
$58.79
Financials
Financial Snapshot
Market Cap
$21.70B
Enterprise Value
$9.56B
Revenue (TTM)
$2.41B
Net Income (TTM)
-$1.48B
Cash & Investments
$10.20B
Net Cash
$9.84B
Free Cash Flow (TTM)
-$456.2M
Operating CF (TTM)
-$247.6M
Debt/Equity
0.02
Cash Runway & Burn Rate
Cash on Hand
$10.20B
Quarterly Burn
$61.9M
Monthly Burn
$20.6M
Est. Runway
~164.8 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $172.4M | $411.8M | $520.8M | $1.35B | $2.07B | $14.06B | $16.55B | $16.78B | $14.83B | $10.20B | |
| Operating Cash Flow | -$52.6M | -$58.2M | -$198.5M | -$13.5M | $889.7M | $13.58B | $5.37B | $207.7M | $438.0M | -$247.6M | |
| Free Cash Flow | -$110.3M | -$126.0M | -$269.6M | -$98.9M | $735.7M | $13.21B | $4.67B | -$244.6M | $269.8M | -$456.2M | |
| Capital Expenditure | -$57.7M | -$67.9M | -$71.1M | -$85.4M | -$154.0M | -$363.3M | -$705.5M | -$452.3M | -$168.2M | -$208.6M | |
| Financing Cash Flow | -$1.6M | $365.2M | $383.3M | $894.7M | $94.2M | -$1.42B | -$778.6M | -$45.9M | -$50.8M | -$330.7M |
R&D Spending
R&D (TTM)
$2.37B
R&D Intensity
98.0%
R&D Growth vs Prior
+17.0%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.6M | $127.6M | $108.6M | $482.3M | $18.98B | $17.31B | $3.82B | $2.75B | $2.76B | $2.41B | |
| R&D Expense | $85.5M | $143.1M | $226.5M | $645.0M | $949.2M | $1.54B | $1.78B | $2.25B | $2.02B | $2.37B | |
| R&D % of Revenue | 138.8% | 112.1% | 208.6% | 133.7% | 5.0% | 8.9% | 46.7% | 81.9% | 73.3% | 98.0% | |
| SG&A | $29.5M | $27.1M | $43.3M | $108.5M | $327.2M | $541.2M | $557.7M | $599.0M | $698.2M | $818.8M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.6M | $127.6M | $108.6M | $482.3M | $18.98B | $17.31B | $3.82B | $2.75B | $2.76B | $2.41B | |
| Cost of Revenue | $9.3M | $13.7M | $17.4M | $59.3M | $2.91B | $3.00B | $599.8M | $541.3M | $616.5M | $726.3M | |
| Gross Profit | $52.3M | $113.9M | $91.2M | $423.0M | $16.07B | $14.32B | $3.22B | $2.21B | $2.14B | $1.69B | |
| R&D | $85.5M | $143.1M | $226.5M | $645.0M | $949.2M | $1.54B | $1.78B | $2.25B | $2.02B | $2.37B | |
| SG&A | $29.5M | $27.1M | $43.3M | $108.5M | $327.2M | $541.2M | $557.7M | $599.0M | $698.2M | $818.8M | |
| Operating Income | -$61.3M | -$53.9M | -$181.5M | -$82.4M | $15.28B | $12.64B | $690.4M | -$1.31B | -$623.9M | -$1.73B | |
| Interest Expense | $651.4K | $1.8M | $1.7M | $1.9M | $5.6M | $15.8M | $7.8M | $13.2M | $13.6M | $26.7M | |
| Pretax Income | -$85.9M | -$47.7M | -$179.4M | -$145.8M | $15.05B | $12.95B | $1.19B | -$677.7M | -$1.01B | -$1.44B | |
| Net Income | -$85.7M | -$48.0M | -$179.1M | $15.2M | $10.29B | $9.43B | $930.3M | -$665.3M | -$1.09B | -$1.48B | |
| EPS (Diluted) | -0.38 | -0.21 | -0.85 | 0.06 | 41.21 | 37.09 | 3.83 | -2.77 | -4.51 | -5.88 | |
| EBITDA | -$74.7M | -$24.0M | -$143.8M | -$105.1M | $15.00B | $13.10B | $1.38B | -$367.1M | -$628.0M | -$527.8M | |
| Shares Out. (M) | 226.86 | 226.86 | 211.50 | 248.53 | 259.70 | 249.80 | 242.70 | 240.40 | 241.70 | 253.00 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $172.1M | $411.5M | $519.1M | $1.21B | $1.69B | $13.88B | $11.66B | $9.76B | $7.67B | $10.20B | |
| Short-Term Investments | $246.0K | $336.0K | $1.7M | $137.2M | $381.6M | $189.4M | $4.89B | $7.02B | $7.16B | $0.00 | |
| Total Current Assets | $189.6M | $449.0M | $560.2M | $1.67B | $15.07B | $21.92B | $19.53B | $18.80B | $16.14B | $15.67B | |
| Total Assets | $374.7M | $653.0M | $797.6M | $2.32B | $15.83B | $23.28B | $23.01B | $22.53B | $21.98B | $20.17B | |
| Total Current Liabilities | $158.5M | $126.1M | $138.1M | $606.0M | $3.48B | $2.95B | $2.07B | $2.52B | $2.14B | $1.83B | |
| Long-Term Debt | $0.00 | $0.00 | $14.8M | $152.9M | $171.6M | $176.2M | $191.0M | $214.7M | $29.9M | $0.00 | |
| Total Liabilities | $422.9M | $386.0M | $304.2M | $946.8M | $3.94B | $3.22B | $2.76B | $3.12B | $2.76B | $2.46B | |
| Stockholders' Equity | -$49.3M | $266.2M | $493.5M | $1.37B | $11.89B | $20.06B | $20.25B | $19.41B | $19.22B | $17.71B | |
| Retained Earnings | -$197.8M | -$245.8M | -$424.8M | -$409.6M | $9.88B | $18.83B | $19.76B | $19.10B | $17.95B | $16.79B |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$52.6M | -$58.2M | -$198.5M | -$13.5M | $889.7M | $13.58B | $5.37B | $207.7M | $438.0M | -$247.6M | |
| Capital Expenditure | -$57.7M | -$67.9M | -$71.1M | -$85.4M | -$154.0M | -$363.3M | -$705.5M | -$452.3M | -$168.2M | -$208.6M | |
| Free Cash Flow | -$110.3M | -$126.0M | -$269.6M | -$98.9M | $735.7M | $13.21B | $4.67B | -$244.6M | $269.8M | -$456.2M | |
| Investing Cash Flow | -$52.5M | -$67.1M | -$77.2M | -$144.8M | -$566.1M | -$35.3M | -$6.95B | -$2.08B | -$2.37B | $771.3M | |
| Financing Cash Flow | -$1.6M | $365.2M | $383.3M | $894.7M | $94.2M | -$1.42B | -$778.6M | -$45.9M | -$50.8M | -$330.7M | |
| Issuance of Stock | $0.00 | $361.7M | $375.4M | $753.0M | $160.9M | $110.5M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$986.4M | -$738.5M | $0.00 | $0.00 | -$406.4M | |
| Net Debt Issuance | -$1.6M | $3.5M | $7.9M | $141.7M | -$66.7M | -$59.1M | -$40.1M | -$45.9M | -$10.9M | $111.4M | |
| Stock Based Comp. | $5.9M | $7.6M | $30.2M | $32.1M | $93.9M | $108.6M | $51.4M | $100.9M | $0.00 | $20.0M | |
| Net Change in Cash | -$131.6M | $239.4M | $107.6M | $691.1M | $482.5M | $12.18B | -$2.21B | -$1.90B | -$931.2M | -$119.1M |
Dilution Tracker
Shares Outstanding
248M
5-Year Share Growth
-2.7%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 226.86 | 226.86 | 211.50 | 248.53 | 259.70 | 249.80 | 242.70 | 240.40 | 241.70 | 253.00 | |
| Change vs Prior % | — | 0.0% | -6.8% | 17.5% | 4.5% | -3.8% | -2.8% | -0.9% | 0.5% | 4.7% | |
| Stock Issuance | $0.00 | $361.7M | $375.4M | $753.0M | $160.9M | $110.5M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$986.4M | -$738.5M | $0.00 | $0.00 | -$406.4M | |
| Stock Based Comp. | $5.9M | $7.6M | $30.2M | $32.1M | $93.9M | $108.6M | $51.4M | $100.9M | $0.00 | $20.0M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 84.9% | 89.3% | 84.0% | 87.7% | 84.7% | 82.7% | 84.3% | 80.3% | 77.6% | 69.9% | |
| Operating Margin % | -99.5% | -42.2% | -167.1% | -17.1% | 80.5% | 73.0% | 18.1% | -47.8% | -22.6% | -71.5% | |
| Net Margin % | -139.1% | -37.6% | -164.9% | 3.2% | 54.2% | 54.5% | 24.4% | -24.2% | -39.6% | -61.3% | |
| EBITDA Margin % | -121.3% | -18.8% | -132.4% | -21.8% | 79.1% | 75.7% | 36.1% | -13.3% | -22.8% | -21.9% | |
| FCF Margin % | -179.1% | -98.8% | -248.3% | -20.5% | 3.9% | 76.3% | 122.2% | -8.9% | 9.8% | -18.9% | |
| ROE % | 173.8% | -18.0% | -36.3% | 1.1% | 86.5% | 47.0% | 4.6% | -3.4% | -5.7% | -8.1% | |
| ROA % | -22.9% | -7.4% | -22.5% | 0.7% | 65.0% | 40.5% | 4.0% | -3.0% | -5.0% | -7.4% | |
| ROIC % | -28.3% | -10.2% | -27.3% | 0.5% | 83.8% | 45.2% | 2.6% | -6.4% | -3.1% | -8.3% | |
| R&D / Revenue % | 138.8% | 112.1% | 208.6% | 133.7% | 5.0% | 8.9% | 46.7% | 81.9% | 73.3% | 98.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 107.1% | -14.9% | 344.1% | 3834.6% | -8.8% | -77.9% | -28.0% | 0.2% | |
| Gross Profit | 0.0% | 0.0% | 117.8% | -19.9% | 363.8% | 3697.9% | -10.9% | -77.5% | -31.4% | -3.2% | |
| Operating Income | 0.0% | 0.0% | 12.1% | -237.0% | 54.6% | 18648.3% | -17.3% | -94.5% | -290.4% | 52.5% | |
| Net Income | 0.0% | 0.0% | 43.9% | -273.0% | 108.5% | 67613.8% | -8.3% | -90.1% | -171.5% | -64.0% | |
| EPS (Diluted) | 0.0% | 0.0% | 44.7% | -304.8% | 106.7% | 72198.2% | -10.0% | -89.7% | -172.3% | -62.8% | |
| Operating Cash Flow | 0.0% | 0.0% | -10.7% | -241.2% | 93.2% | 6690.4% | 1426.1% | -60.4% | -96.1% | 110.9% | |
| Free Cash Flow | 0.0% | 0.0% | -14.3% | -113.9% | 63.3% | 843.9% | 1696.1% | -64.7% | -105.2% | 210.3% | |
| R&D Expense | 0.0% | 0.0% | 67.3% | 58.3% | 184.8% | 47.2% | 61.9% | 16.0% | 26.4% | -10.3% | |
| SG&A Expense | 0.0% | 0.0% | -8.2% | 60.0% | 150.6% | 201.6% | 65.4% | 3.0% | 7.4% | 16.6% | |
| Total Assets | 0.0% | -3.9% | 74.3% | 22.2% | 190.7% | 582.8% | 47.0% | -1.2% | -2.1% | -2.4% | |
| Book Value / Share | 0.0% | 0.0% | 653.9% | 98.3% | 149.7% | 736.6% | 69.1% | 2.1% | -4.0% | -1.5% | |
| Debt | 0.0% | 88.8% | 7.7% | 36.9% | 223.5% | 25.6% | -29.6% | 3.3% | 16.0% | 5.1% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | -6.8% | 17.5% | 4.5% | -3.8% | -2.8% | -0.9% | 0.5% |
Valuation
P/E (TTM)At Loss
10Y Low / Med / High3.68 / 24.67 / 1107.97
P/S8.04
10Y Low / Med / High1.97 / 9.62 / 58.84
P/B1.10
10Y Low / Med / High1.02 / 4.65 / 12.95
EV/EBITDAAt Loss
10Y Low / Med / High1.56 / 3.59 / 8.37
EV/Revenue3.96
10Y Low / Med / High1.18 / 6.16 / 54.74
P/FCFAt Loss
10Y Low / Med / High2.58 / 72.58 / 75.19
Intrinsic Value Models (per share)
DCF Value
$46.34
Tangible Book / Share
$64.71
Net Current Assets / Share
$53.29
Graham Net-Net
$51.44
Cash / Share
$58.79
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -31.22 | -59.13 | -35.54 | 1107.97 | 5.17 | 3.68 | 24.67 | -39.73 | -17.97 | -13.29 | |
| P/S Ratio | 43.69 | 22.08 | 58.84 | 32.56 | 2.91 | 1.97 | 6.02 | 9.62 | 7.10 | 8.04 | |
| P/B Ratio | -54.59 | 10.58 | 12.95 | 11.45 | 4.65 | 1.70 | 1.13 | 1.36 | 1.02 | 1.10 | |
| EV/EBITDA | -34.39 | -102.67 | -41.34 | -140.19 | 3.59 | 1.56 | 8.37 | -46.16 | -19.39 | -22.34 | |
| EV/Revenue | 41.71 | 19.28 | 54.74 | 30.55 | 2.84 | 1.18 | 3.02 | 6.16 | 4.42 | 3.96 |
Analyst Estimates & Quality
Altman Z-Score
6.62
Safe
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $1.87B | $1.87B | $2.30B |
| Net Income | -$1.39B | -$1.37B | -$911.7M |
| EPS | $-5.74 | $-5.65 | $-4.59 |
| # Analysts (EPS) | 6 | 9 | 10 |
Dividends
Frequency
Irregular
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Jun 2, 2022 | Jun 17, 2022 | $2.11 | Irregular |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Other Sales Transactions | $33.0M | — | — | — | — | — |
| Commercial | — | $71.38B | — | $3.82B | — | — |
| Research And Development | — | $205.4M | $116.0M | $3.5M | — | — |
| Other Sales | — | — | — | — | $319.0M | $261.6M |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| GERMANY | $20.6M | $2.24B | — | $482.7M | $706.9M | $759.1M |
| UNITED STATES | — | $14.64B | $12.71B | $3.01B | $1.85B | $1.79B |
| DELAWARE | — | — | $3.03B | — | — | — |
| Rest of the World | — | — | — | — | $196.4M | $11.1M |
| IRELAND | — | — | — | — | — | $304.8M |